Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris, +18

Annals of Oncology

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

John Crown, H. A. Burris, Frances M. Boyle, +7

Breast Cancer Research and Treatment

Gastrointestinal OncologyMedicineCancer ManagementGastroenterologyPathology +6

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

Mace L. Rothenberg, A. Sharma, Geoffrey R. Weiss, +12

Annals of Oncology

Malignant DiseaseMedicineClinical TrialsPharmacotherapyRefractory Solid Tumors +6

Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

Andrés Cervantes, María Alsina, Josep Tabernero, +17

Journal of Clinical Oncology

Solid TumorsLiver InvolvementNovel Rnai TherapeuticPathologyPharmacotherapy +15

A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

José Baselga, Maja J. De Jonge, Jordi Rodón, +7

Journal of Clinical Oncology

PathologyPi3k InhibitorPharmacotherapyAdvanced Solid TumorsTumor Biology +14

A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)

M. Beeram, H. A. Burris, Shanu Modi, +6

Journal of Clinical Oncology

Breast OncologyImmunologyPharmacotherapyImmunotherapeuticsImmunotherapy +21

Clinical activity of GW572016 in EGF10003 in patients with solid tumors

M. Versola, H. A. Burris, Sharon Jones, +6

Journal of Clinical Oncology

Vegf InhibitionSerum Vegf LevelsSolid TumorsMalignant DiseaseMedicine +13

A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment.

Natalie R. Dickson, Suzanne F. Jones, H. A. Burris, +6

Journal of Clinical Oncology

Chemoprevention StrategyPharmacotherapyAdvanced Solid TumorsTumor BiologyPre-clinical Pharmacology +16

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC)

Scott N. Holden, M. Beeram, IE Krop, +6

Journal of Clinical Oncology

Breast OncologyT. T-dm1ImmunologyReversible TcpPharmacotherapy +19

A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study

Andrew Jacobs, H. A. Burris, Saul E. Rivkin, +3

Journal of Clinical Oncology

Surgical OncologyOral TopoisomeraseCancer ManagementPathologyPharmacotherapy +15